Protocol for the Examination of Resection Specimens from Patients with Renal Cell Carcinoma

Version: 4.2.0.0
Protocol Posting Date: June 2024
CAP Laboratory Accreditation Program Protocol Required Use Date: March 2025

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nephrectomy</td>
<td>Includes specimens designated partial, total, or radical nephrectomy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal cell carcinomas</td>
<td>Includes all renal cell carcinoma types</td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy (use optional Kidney Biopsy protocol)</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (e.g., following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
<tr>
<td>Low malignant potential tumors such as clear cell papillary renal tumor, multilocular cystic renal neoplasm of low malignant potential, and low-grade oncocytic neoplasms</td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urothelial tumors (use Ureter, Renal Pelvis protocol)</td>
</tr>
<tr>
<td>Nephroblastic (Wilms) tumors (use Wilms Tumor Resection protocol)</td>
</tr>
<tr>
<td>Hematopoietic neoplasms (use the Precursor and Mature Lymphoid neoplasm, Myeloid and Mixed / Ambiguous Lineage Neoplasms or Plasma Cell Malignancies and Immunoglobulin Deposition Related Disorders protocol)</td>
</tr>
<tr>
<td>Sarcoma (use the Soft Tissue protocol)</td>
</tr>
</tbody>
</table>

Authors
Paari Murugan, MD, FCAP*; Robert W. Allan, MD*; Lara R. Harik, MD, FCAP*; Gladell P. Paner, MD, FCAP; John R. Srigley, MD; Mahul B. Amin, MD; Sean R. Williamson, MD; Ying-Bei Chen, MD, PhD; Kiril Trpkov, MD; Michelle S. Hirsch, MD, PhD; Steven C. Smith, MD, PhD; Holger Moch, MD; Peter A. Humphrey, MD, PhD; Maria Carlo, MD; Viraj A. Master, MD, PhD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- **Optional data elements** are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (i.e., secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
- The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report i.e., all required elements must be in the synoptic portion of the report in the format defined above.
Summary of Changes
v 4.2.0.0

- Title and cover page update
- WHO 5th edition update to content and explanatory notes
- pTNM Classification update
- Addition of required (core) question “Histologic Features”
- LVI question update from optional to core element and terminology changed from “Lymphovascular Invasion” to “Lymphatic and / or Vascular Invasion”
Reporting Template
Protocol Posting Date: June 2024
Select a single response unless otherwise indicated.

CASE SUMMARY: (KIDNEY: Nephrectomy)
Standard(s): AJCC-UICC 8

SPECIMEN (Note A)

Procedure
___ Partial nephrectomy
___ Total (simple) nephrectomy
___ Radical nephrectomy
___ Other (specify): _________________
___ Not specified

Specimen Laterality
___ Right
___ Left
___ Other (specify): _________________
___ Not specified

TUMOR

Tumor Focality
___ Unifocal
___ Multifocal (specify numbers of tumors): _________________

+Tumor Site (select all that apply)
___ Upper pole
___ Middle
___ Lower pole
___ Other (specify): _________________
___ Not specified

Tumor Size
If multiple tumors are present, document the size of the largest tumor.
___ Greatest dimension in Centimeters (cm): _________________ cm
   +Additional Dimension in Centimeters (cm): ____ x ____ cm
   +Greatest Dimension of Other Tumor(s) in Centimeters (cm) (repeat as needed):
      __________________ cm
___ Cannot be determined (explain): __________________

Histologic Type (Note B)
Clear cell tumors
___ Clear cell renal cell carcinoma
Multilocular cystic renal neoplasm of low malignant potential

Papillary renal tumors
  Papillary renal cell carcinoma

Oncocytic and chromophobe renal tumors
  Chromophobe renal cell carcinoma
  Other oncocytic tumors of the kidney (specify): ______________________

Collecting duct tumors
  Collecting duct carcinoma

Other renal tumors
  Clear cell papillary renal cell tumor
  Mucinous tubular and spindle renal cell carcinoma
  Tubulocystic renal cell carcinoma
  Acquired cystic disease-associated renal cell carcinoma
  Eosinophilic solid and cystic renal cell carcinoma
  Renal cell carcinoma, NOS (unclassified)

Molecularly defined renal carcinomas
  TFE3-rearranged renal cell carcinoma
  TFEB-altered renal cell carcinoma
  ELOC (formerly TCEB1)-mutated renal cell carcinoma
  Fumarate hydratase-deficient renal cell carcinoma
  Succinate dehydrogenase-deficient (SDH) renal cell carcinoma
  ALK-rearranged renal cell carcinoma
  SMARCB1-deficient renal medullary carcinoma

Other
  Renal cell carcinoma, subtype pending additional studies
  Other histologic type not listed (specify): ______________________

Histologic Type Comment: ______________________

Histologic Grade (WHO / ISUP) (Note C)
See table for renal carcinoma subtype grading requirements
  G1, nucleoli absent or inconspicuous at 400x magnification
  G2, nucleoli conspicuous and visible at 400x magnification, not prominent at 100x magnification
  G3, nucleoli conspicuous at 100x magnification
  G4, extreme nuclear pleomorphism and / or multinucleated giant cells and / or rhabdoid and / or sarcomatoid differentiation (specify): ______________________
  GX, cannot be assessed
  Not applicable: ______________________

Histologic Grade Comment: ______________________

Tumor Extent (Note D) (select all that apply)
  Limited to kidney
  Extends into perinephric tissue (beyond renal capsule)
  Extends into renal sinus
  Extends into pelvicalyceal system
  Extends into renal vein or its segmental branches
  Extends into inferior vena cava
  Extends beyond renal Gerota's fascia (renal fascia)
___ Directly invades adrenal gland (T4)
___ Involves adrenal gland non-contiguously (M1)
___ Extends into other organ(s) / structure(s) (specify): _________________
___ Cannot be determined: _________________

Histologic Features (Note E) (select all that apply)
___ Sarcomatoid or rhabdoid features not identified
___ Sarcomatoid features present
   +Percentage of Sarcomatoid Element: _________________ %
___ Rhabdoid features present
   +Percentage of Rhabdoid Element: _________________ %
___ Cannot be determined: _________________

Tumor Necrosis (Note F)
___ Not identified
___ Present
   +Percentage of Tumor Necrosis: _________________ %
___ Cannot be determined: _________________

Lymphatic and / or Vascular Invasion (excluding renal vein and its segmental branches and inferior vena cava)
___ Not identified
___ Present
___ Cannot be determined: _________________

+Tumor Comment: _________________

MARGINS (Note G)

Margin Status
___ All margins negative for invasive carcinoma
___ Invasive carcinoma present at margin

Margin(s) Involved by Invasive Carcinoma (select all that apply)
# For partial nephrectomy only
___ Renal parenchymal#: _________________
___ Renal capsular#: _________________
___ Renal sinus soft tissue#: _________________
___ Renal hilar soft tissue: _________________
___ Renal vein (tumor invades or is adherent to vein wall at margin): _________________
___ Ureteral: _________________
___ Perinephric fat: _________________
___ Gerota's fascia: _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________
___ Not applicable

+Margin Comment: ____________________

REGIONAL LYMPH NODES

Regional Lymph Node Status
___ Not applicable (no regional lymph nodes submitted or found)
___ Regional lymph nodes present
___ All regional lymph nodes negative for tumor
___ Tumor present in regional lymph node(s)

Number of Lymph Nodes with Tumor
___ Exact number (specify): _________________
___ At least (specify): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

+Nodal Site(s) with Tumor (select all that apply)
___ Hilar: _________________
___ Precaval: _________________
___ Interaortocaval: _________________
___ Paracaval: _________________
___ Retrocaval: _________________
___ Preaortic: _________________
___ Paraaortic: _________________
___ Retroaortic: _________________
___ Other (specify): _________________

+Size of Largest Nodal Metastatic Deposit
  Specify in Centimeters (cm)
___ Exact size: _________________ cm
___ At least: _________________ cm
___ Greater than: _________________ cm
___ Less than: _________________ cm
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

+Specify Nodal Site with Largest Metastatic Deposit: _________________

+Extranodal Extension (ENE)
___ Not identified
___ Present
  +Specify Location of Involved Lymph Node(s): _________________
___ Cannot be determined: _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

Number of Lymph Nodes Examined
___ Exact number (specify): _________________
___ At least (specify): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

+Regional Lymph Node Comment: _________________

DISTANT METASTASIS

Distant Site(s) Involved, if applicable
___ Not applicable
___ Specify site(s): _________________
___ Cannot be determined: _________________

pTNM CLASSIFICATION (AJCC 8th Edition) (Note H)
Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.

Modified Classification (required only if applicable) (select all that apply)
___ Not applicable
___ y (post-neoadjuvant therapy)
___ r (recurrence)

pT Category
___ pT not assigned (cannot be determined based on available pathological information)
___ pT0: No evidence of primary tumor
___ pT1: Tumor less than or equal to 7 cm in greatest dimension, limited to the kidney
___ pT1a: Tumor less than or equal to 4 cm in greatest dimension, limited to the kidney
___ pT1b: Tumor greater than 4 cm but less than or equal to 7 cm in greatest dimension limited to the kidney
___ pT1 (subcategory cannot be determined)
___ pT2: Tumor greater than 7 cm in greatest dimension, limited to the kidney
___ pT2a: Tumor greater than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney
___ pT2b: Tumor greater than 10 cm, limited to the kidney
___ pT2 (subcategory cannot be determined)
___ pT3: Tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota’s fascia
___ pT3a: Tumor extends into the renal vein or its segmental branches, or invades the pelvicalyceal system, or invades perirenal and / or renal sinus fat but not beyond Gerota’s fascia
___ pT3b: Tumor extends into the vena cava below the diaphragm
___ pT3c: Tumor extends into the vena cava above the diaphragm or invades the wall of the vena cava
___ pT3 (subcategory cannot be determined)
___ pT4: Tumor invades beyond Gerota’s fascia (including contiguous extension into the ipsilateral adrenal gland)

T Suffix (required only if applicable)
___ Not applicable
___ (m) multiple primary synchronous tumors in a single organ
pN Category
___ pN not assigned (no nodes submitted or found)
___ pN not assigned (cannot be determined based on available pathological information)
___ pN0: No regional lymph node metastasis
___ pN1: Metastasis in regional lymph node(s)

pM Category (required only if confirmed pathologically)
___ Not applicable - pM cannot be determined from the submitted specimen(s)
___ pM1: Distant metastasis (including non-contiguous adrenal gland involvement)

ADDITIONAL FINDINGS (Note !)

Additional Findings in Kidney (select all that apply)
___ Insufficient tissue
___ No significant pathologic change identified
___ Glomerular disease (specify type): __________________
___ Tubulointerstitial disease (specify type): __________________
___ Vascular disease (specify type): ___________________
___ Cyst(s) (specify type): __________________
___ Papillary adenoma(s): ____________________
___ Other (specify): ___________________

COMMENTS

Comment(s): __________________
Explanatory Notes

A. Specimen Type
A standard radical nephrectomy specimen consists of the entire kidney including the calyces, pelvis, and a variable length of ureter. Although in the past the adrenal gland was considered a standard part of radical nephrectomy, current surgical recommendations are that the adrenal gland should not be removed unless there is suspicion for involvement. The entire perirenal fatty tissue is removed to the level of Gerota's fascia, a membranous structure that is similar to the consistency of the renal capsule that encases the kidney in perirenal fat. Variable lengths of the major renal vessels at the hilus are submitted. Total nephrectomy is a similar procedure but typically performed for clinical presumption of benign disease and may not extend to Gerota's fascia.

Regional lymphadenectomy is not generally performed even with a radical nephrectomy unless there is clinical suspicion of involved or abnormal lymph nodes. A few lymph nodes may occasionally be found in the renal hilus around major vessels. Other regional lymph nodes (e.g., paracaval, para-aortic, and retroperitoneal) may be submitted separately.

A partial nephrectomy specimen may vary from an enucleation of the tumor with almost no normal tissue to a partial resection containing variable portions of calyceal or renal pelvic collecting system. The perirenal fat immediately overlying the resected portion of the kidney is usually included, but not to the level of Gerota's fascia. The perinephric fat may also be detached by the surgeon to improve visualization of the tumor, and either submitted detached in the same specimen, or as a separate specimen.

B. Histologic Type
This protocol was updated to incorporate the changes made in the 5th edition WHO Urinary and Male Genital Tumors Classification.1

The updated entities that should be reported using the kidney cancer protocol are listed below:

**Clear cell renal tumors**
- Clear cell renal cell carcinoma
- Multilocular cystic renal neoplasm of low malignant potential

**Papillary renal tumors**
- Papillary renal cell carcinoma

**Oncocytic and chromophobe renal cell tumors**
- Chromophobe renal cell carcinoma
- Other oncocytic tumors of the kidney

**Collecting duct tumors**
- Collecting duct carcinoma

**Other renal tumors**
- Clear cell papillary renal cell tumor
- Mucinous tubular and spindle cell carcinoma
- Tubulocystic renal cell carcinoma
- Acquired cystic disease-associated renal cell carcinoma
- Eosinophilic solid and cystic renal cell carcinoma
- Renal cell carcinoma, NOS
Molecularly defined renal carcinoma

- TFE3-rearranged renal cell carcinomas
- TFEB-altered renal cell carcinomas
- ELOC (formerly TCEB1)-mutated renal cell carcinoma
- Fumarate hydratase-deficient renal cell carcinoma
- Succinate dehydrogenase-deficient renal cell carcinoma
- ALK-rearranged renal cell carcinomas
- SMARCB1-deficient renal medullary carcinoma

The changes made in the 5th WHO edition are summarized below and the reader is encouraged to reference the updated manuscript.

Papillary renal cell carcinoma: Subclassification into type 1 and type 2 is no longer recommended. This reflects the recognition that many tumors characterized as type 2 papillary renal cell carcinoma now represent other distinct entities (e.g., Fumarate hydratase-deficient renal cell carcinoma).

Other oncocytic tumors of the kidney: This is a heterogeneous group of renal tumors with eosinophilic/oncocytic cells with oncocytoma-like and/or chromophobe renal cell carcinoma-like features. This includes hybrid oncocytic tumors (HOCT) that may occur sporadically or associated with Birt-Hogg-Dube syndrome; the emerging entities of eosinophilic vacuolated tumor (EVT), low-grade oncocytic tumor (LOT) and other eosinophilic/oncocytic tumors with intermediate (borderline) features.

Clear cell papillary renal cell tumor (CCPRCT): Renamed from carcinoma to tumor to reflect its indolent behavior.

Eosinophilic solid and cystic renal cell carcinoma: This was recognized as a separate entity characterized by solid and cystic architecture with voluminous eosinophilic cytoplasm, frequent (but not required) keratin 20 reactivity and typically negative keratin 7 expression. The clinical behavior is indolent in the great majority of cases and these tumors may occur in association with tuberous sclerosis complex or sporadically. In both settings, there are alterations in the TSC1/2 genes.

Renal cell carcinoma, NOS: This category should be reserved for carcinomas that cannot be placed into one of the morphologically and molecularly defined categories. These are usually high-grade. Low-grade oncocytic tumors that are difficult to classify should be placed in the "Other oncocytic tumors of the kidney" group.

Molecularly defined renal cell carcinoma
The category of molecularly defined renal carcinoma was added to the 5th edition WHO to include carcinomas that demonstrate characteristic molecular alterations that define these tumor types.

TFE3-rearranged renal cell carcinomas: This was formerly called Xp11 translocation renal cell carcinoma. These tumors morphologically often show mixed papillary and solid architecture, with mixed clear and eosinophilic cytoplasm, sometimes with scattered psammoma bodies. These tumors are characterized by TFE3 rearrangements, revealed by nuclear expression of TFE3 protein or preferably, demonstration of TFE3 rearrangement by break-apart FISH or sequencing methods. Other immunohistochemical markers that may be positive include variable melanocytic markers, cathepsin K, and GPNMB.
**TFEB**-altered renal cell carcinoma: This category encompasses renal carcinoma that possess either a TFEB rearrangement or TFEB/6p21 amplification. TFEB rearranged carcinomas frequently display a biphasic pattern with smaller cells clustering around basement membrane-like material surrounded by larger epithelioid cells. However, other patterns can also be present that may overlap with clear cell renal cell carcinoma, TFE3 rearranged renal cell carcinoma, and tumors with oncocytic features. TFEB amplified carcinoma is less characteristic and may appear poorly differentiated and infiltrative with papillary and oncocytic features. Useful markers for detection of TFEB rearranged carcinomas include the melanocytic markers melan-A and HMB45, cathepsin K, or nuclear reactivity for TFEB protein. TFEB amplified carcinomas may also have melanocytic marker and cathepsin K positivity, and some are positive for keratin 20, overlapping with the immunohistochemical pattern of eosinophilic solid and cystic renal cell carcinoma. If a break-apart FISH method is used, TFEB amplified carcinomas show numerous copies of the TFEB region, usually without rearrangement. Other genes at 6p21, such as VEGFA, are typically included in the amplicon. Whereas TFE3/TFEB rearranged carcinomas have a tendency to occur in younger patients (although not always), TFEB amplified carcinomas appear to occur in older patients and have a worse prognosis.2,3

**ELOC** mutated renal cell carcinoma: The ELOC gene was formerly known as TCEB1, therefore, this tumor was formerly known as TCEB1 mutated renal cell carcinoma. These tumors tend to be small and of low stage, with prominent fibromuscular bands, overlapping with renal cell carcinoma with leiomyomatous or fibromyomatous stroma. Keratin 7 appears to be consistently expressed, and the tumor is characterized by bi-allelic inactivation of ELOC. Data are limited; however, behavior appears mostly favorable.

Fumarate hydratase (FH) deficient renal cell carcinoma: This entity was previously known as hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma. This is typically an aggressive tumor with variable architecture patterns (papillary, solid, tubulocystic, cribriform) with high-grade appearing cells with prominent bright red macronucleoli and perinucleolar clearing. The morphological spectrum was recently expanded to include cases with low-grade oncocytic morphology. These tumors have mutations in the fumarate hydratase (FH) gene which can be demonstrated by lack of FH protein expression (“loss”) and 2-succinocysteine (2SC) reactivity by immunohistochemistry. Rarely, mutated tumors may show focal or patchy FH staining, presumably due to a dysfunctional protein that remains recognizable by the antibody. Most patients are thought to have germline FH alterations and thus the hereditary leiomyomatosis and renal cell carcinoma syndrome, accompanied also by skin and uterine leiomyomas (in females); however, a subset of tumors appear to occur due to somatic FH mutations in the absence of the syndrome.

Succinate dehydrogenase-deficient renal cell carcinoma: This rare renal cell carcinoma typically has bland, bubbly eosinophilic cells, overlapping with oncocytic tumors such as oncocytoma and chromophobe renal cell carcinoma. The most diagnostic finding is immunohistochemistry for SDHB showing abnormal absence of staining in the tumor cells (“loss”) serving as a surrogate marker for SDH gene complex alterations. Contrasting to most other oncocytic tumors, these neoplasms are typically negative for KIT and entirely negative for keratin 7. Most patients have germline SDHB alterations and thus the hereditary SDH-deficient tumor syndrome.

**ALK**-rearranged renal cell carcinoma: ALK-rearranged renal cell carcinoma is newly included in the 5th edition WHO Classification. These tumors show variable morphology, including solid, papillary, and
cribriform patterns. Mucin production is a common feature. Tumors are characterized by rearrangements of ALK demonstrated by positive immunohistochemistry or abnormal FISH. Although very rare, this tumor type may be particularly relevant for treatment, as ALK inhibitors appear to have benefit.

**SMARCB1-deficient renal medullary carcinoma:** SMARCB1-deficient renal medullary carcinoma was previously designated renal medullary carcinoma but has been brought under the umbrella of molecularly defined renal cell carcinoma. This tumor type retains the classical association with renal medullary location and strong association with sickle cell trait or rarely other hemoglobinopathies. The name was updated to include the characteristic loss of SMARCB1 (also known as INI1, BAF47) demonstrable by immunohistochemistry that serves as a surrogate for SMARCB1 inactivation on 22q11.23. An important point to emphasize is that this category should be reserved for those tumors with medullary location/phenotype that are very frequently, but not always associated with sickle cell trait. Other renal cell carcinoma subtypes, for example clear cell with sarcomatoid transformation or FH deficient renal cell carcinoma, may show secondary SMARCB1 loss and should be categorized according to the underlying morphologic/genetic feature.

The category of “Other histologic type not listed (specify)” can be used to diagnose entities that are emerging provisional entities such as, biphasic hyalinizing psammomatous renal cell carcinoma, or thyroid-like follicular renal cell carcinoma.

In recognition of the increasing number of molecularly defined renal cell carcinomas, a category of “Renal cell carcinoma, subtype pending additional studies” has been added to the protocol. Since many pathologists will not have immediate access to the immunohistochemistry (IHC) and molecular studies required to define these rare tumors, this category facilitates preliminary sign-out while awaiting reference lab results. An addendum report should be issued on completion of the additional studies.

References


C. Histologic Grade

Grade should be assigned based on the highest grade cells present in a single high power field rather than the most predominant pattern. Grade is based upon the degree of nucleolar predominance (grades 1-3) and presence of nuclear pleomorphism, including giant cells, sarcomatoid or rhabdoid features (grade 4). This grading system has been validated for both clear cell and papillary renal cell carcinoma; however, it has not been validated for other RCC subtypes. Nevertheless, the WHO/ISUP grade should be included for descriptive purposes. The following table outlines the utility of grading in the different subtypes of renal carcinoma.
## Category and Tumor Type

<table>
<thead>
<tr>
<th>RCC subtypes validated for WHO/ISUP grading</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear cell RCC</td>
<td></td>
</tr>
<tr>
<td>Papillary RCC</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RCC subtypes where WHO/ISUP grading is clearly not applicable</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromophobe RCC</td>
<td>WHO/ISUP grading is not applicable; alternative schemes have been proposed, such as chromophobe tumor grade and grading by necrosis and sarcomatoid change</td>
</tr>
<tr>
<td>TFE3-rearranged RCC</td>
<td>Studies show that WHO/ISUP grade may not be useful</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RCC subtypes where WHO/ISUP grading is potentially useful</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDH-deficient RCC</td>
<td>Low and high-grade features using Fuhrman or WHO/ISUP grading seem to be associated with outcome, suggesting the potential value of nuclear grading</td>
</tr>
<tr>
<td>Mucinous tubular and spindle cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>ELOC-mutated RCC&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>TFEB-altered RCC</td>
<td>WHO/ISUP grade may help separate aggressive TFEB-amplified RCC from TFEB-rearranged RCC</td>
</tr>
<tr>
<td>RCC, NOS</td>
<td>Includes tumors with heterogeneous morphology; providing information on nuclear grade&lt;sup&gt;b&lt;/sup&gt; would be helpful to communicate potential prognosis to clinicians</td>
</tr>
<tr>
<td>FH-deficient RCC including HLRCC-RCC</td>
<td>The vast majority of tumors have high-grade&lt;sup&gt;a&lt;/sup&gt; nuclei, in keeping with their aggressive behavior, but rare low-grade potentially indolent tumors have been reported; therefore, specifying the low-grade tumors (to distinguish from the more common high-grade tumors) may be helpful</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inherently aggressive RCC subtypes irrespective of WHO/ISUP grading</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collecting duct carcinoma</td>
<td>Inherent high-grade nuclei and almost uniform aggressive clinical course in these tumor types obviates use of nuclear grading</td>
</tr>
<tr>
<td>SMARCB1-deficient renal medullary carcinoma</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RCC subtypes where WHO/ISUP grading is potentially misleading</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tubulocystic carcinoma</td>
<td>Nuclear grading&lt;sup&gt;b&lt;/sup&gt; may be problematic because of pure or predominantly high-grade–appearing nuclei despite the overall indolent behavior of tumor types</td>
</tr>
<tr>
<td>Acquired cystic disease-associated RCC</td>
<td></td>
</tr>
<tr>
<td>Eosinophilic solid and cystic RCC and eosinophilic vacuolated tumor</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Renal epithelial neoplasms where low WHO/ISUP grade features are essential for accurate histological classification</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Papillary adenoma</td>
<td></td>
</tr>
<tr>
<td>Multilocular cystic renal neoplasm of low malignant potential</td>
<td></td>
</tr>
<tr>
<td>Clear cell papillary renal cell tumor</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Renal epithelial neoplasm with no or limited data on grading or behavior</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALK-rearranged RCC</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other oncocytic tumors</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other oncocytic tumors</td>
<td>Other oncocytic tumors in the 5 edition WHO classification are low or high-grade tumors even though their histological features are not predictive of clinical behavior</td>
</tr>
</tbody>
</table>
FH, fumarate hydratase; HLRCC-RCC, hereditary leiomyomatosis, and renal cell carcinoma syndrome–associated renal cell carcinoma; RCC, renal cell carcinoma; SDH, succinate dehydrogenase.

\(^a\)Formerly TCEB1-mutated RCC. \(^b\)Nuclear grade: used here when a grading system is not specified in the literature, or when the data span the Fuhrman and WHO/ISUP grading systems or when they mention nuclear grade without specific criteria. WHO/ISUP grading may be generally inferred from nuclear features, with G1 and G2 tumors being low-grade and G3 and G4 tumors being high-grade.

References

D. Extent of Tumor
A careful gross analysis and description of tumor extension in a nephrectomy specimen is important and should guide blocking of tissue samples for histologic assessment.\(^1\) Careful documentation of the tumor extension beyond kidney into the renal vein, renal sinus, perinephric fat and Gerota's fascia (pT4) provides important staging information.\(^2,3\) Histologic sampling should be utilized to confirm the presence of renal vein invasion. Perinephric adipose tissue (outer surface of the kidney away from the renal sinus) extension is present when there is one or more of the following features: (1) direct tumor invasion of perinephric adipose tissue (2) irregular tongues of tumor extending beyond the renal capsule and (3) separate tumor nodules distributed in the adjacent perinephric adipose tissue beyond the renal capsule or tumor pseudo capsule. Invasion of the renal capsule without extension into perinephric soft tissue has no adverse prognostic significance\(^4\) and carcinomas with this finding are not upstaged to pT3.

The renal sinus is an anatomical compartment separating the renal parenchyma from the collecting system (renal pelvis and calyces).\(^1,5\) This area contains abundant adipose tissue, lymphatics, and thin-walled veins. In recent years, the definition of renal sinus involvement has been clarified and includes the following: (1) tumor in contact with renal sinus fat, (2) tumor infiltrating the loose connective tissue of the sinus that is clearly beyond the renal parenchyma, and (3) involvement of any endothelial lined space within the renal sinus (with or without mural smooth muscle), including lymphatics.\(^1,6,7\)
Renal sinus involvement in renal cell carcinoma is an under-recognized phenomenon.\(^5\) The renal sinus is an important pathway of spread of renal cell carcinoma (Figure 1, A and B). The renal sinus should be carefully assessed and generously sampled to detect renal sinus fat and vessel involvement, particularly in larger tumors (≥7cm), as renal sinus invasion is present in greater than 90% of these tumors.\(^1,6\) As tumor size increases over 4 cm, the likelihood of renal sinus invasion increases dramatically.\(^8\)

Although earlier literature suggested that renal sinus involvement predicts a more aggressive outcome than peripheral perinephric fat invasion, more recent studies show the presence of multiple patterns of extrarenal extension is associated with a higher risk of disease progression and cancer-related death after radical nephrectomy compared to isolated involvement of the perinephric fat, renal sinus fat, or renal vein, which carry similar prognostic weight.\(^8,9,10,11\) If a tumor thrombus is present in the renal vein it is important to determine if the tumor is confined to the renal vein (pT3a), or whether it extends into inferior vena cava (pT3b/c) or invades into the wall of the inferior vena cava (pT3c). When renal carcinoma involves the adrenal gland, it is important to document whether the involvement is contiguous spread of tumor (pT4) or a separate (noncontiguous) nodule of carcinoma, the latter representing metastatic disease (pM1) (Figure 2).\(^2,9,12\) Additionally, the presence of metastatic disease in any other accompanying organs would be considered pM1 disease for the purpose of the TNM system.\(^2\)
**Figure 1.** A: Diagram showing the renal sinus fat (S) and its rich venous system that envelops the collecting system. The renal capsule terminates (arrow) just inside the vestibule of the hilus. B: A renal malignancy is constrained by the renal capsule (arrow), yet no fibrous capsule impedes its growth into the vascular tissue of the renal sinus (curved arrows). From Bonsib et al. Reproduced with permission of the *American Journal of Surgical Pathology.* © 2000 Wolters Kluwer Health.

**Figure 2.** Diagram showing relationship between local tumor extension and pT designation. When a tumor shows direct invasion into the perirenal fat or renal sinus fat, it is designated as pT3a. A tumor that directly invades the adrenal gland is designated as pT4, while a tumor that shows discontinuous (noncontiguous) involvement of the adrenal gland is considered metastatic (M1).
References


E. Sarcomatoid and Rhabdoid Features

Sarcomatoid carcinoma is not a specific morphologic or genetic subtype of renal cell carcinoma but is considered a pattern of dedifferentiation of different renal carcinoma subtypes. Sarcomatoid change in a renal cell carcinoma is associated with an adverse outcome. Sarcomatoid morphology may be found in any histologic subtypes of renal cell carcinomas, including clear cell, papillary, chromophobe, collecting duct, and other rare and unclassified subtypes. When the background carcinoma subtype is recognized, it should be specified under histologic type (see Note B). Pure sarcomatoid carcinoma or sarcomatoid carcinoma associated with epithelial elements that do not conform to usual renal carcinoma cell types should be considered as renal cell carcinoma, NOS. Sarcomatoid morphology is also incorporated into the WHO/ISUP grading system as grade 4.

Rhabdoid features, like sarcomatoid features, are a characteristic of high-grade disease. Rhabdoid cells have abundant eosinophilic cytoplasm with an eccentric nucleus and often a prominent nucleolus. These cells mimic rhabdomyoblasts but do not show true skeletal muscle differentiation. Rhabdoid features are associated with adverse outcomes, and about 25% concurrently show sarcomatoid features. Rhabdoid morphology is also by definition WHO/ISUP grade 4.
There is some indication that the percentage of sarcomatoid component in a renal cell carcinoma has prognostic importance.\(^2\)\(^,\)\(^4\)\(^,\)\(^8\) A recent study has also shown that the extent of WHO/ISUP grade 4 component in a tumor influences outcome for clear cell RCC irrespective of type of grade 4 histology (sarcomatoid, rhabdoid or extreme atypia). This study demonstrated that although cancers with overall grade 4 morphology had a significantly worse outcome than grade 3 cancers, those with <10% grade 4 component were not associated with a significant survival difference from grade 3 cancers. In addition, there was a significant difference in survival between tumors with <10% versus >50% grade 4 areas.\(^9\)

References


F. Necrosis

Tumor necrosis is an important prognostic factor in renal cell carcinoma.\(^1\)\(^2\)\(^3\) The prognostic significance of necrosis independent of tumor stage has been identified in clear cell and chromophobe renal cell carcinoma.\(^2\)\(^4\) In addition, tumor-associated necrosis has been shown to be an important prognostic factor for clear cell RCC, independently of WHO/ISUP grade. The prognostic significance of necrosis in papillary renal cell carcinoma is controversial. Large papillary carcinomas commonly display cystic necrosis and yet do not exhibit extra renal spread.\(^5\) Tumor necrosis cannot be assessed as a prognostic factor when patients have undergone presurgical arterial embolization, as tumor-type necrosis cannot be definitively distinguished from treatment effect.

At present, the prognostic significance of the extent of necrosis is unclear; however, it is recommended that this be recorded as a percentage incorporating the best estimate of extent, based upon macroscopic
and confirmatory microscopic evaluation.3 Extensive necrosis in the setting of a low-grade RCC appears to be associated with a more favorable prognosis.5

References

G. Margins

Partial Nephrectomy: The renal parenchymal margin should be inked and histologically assessed; preferably utilizing perpendicular sections.1 Sections demonstrating the relationship of the tumor to perinephric adipose tissue (when present), renal capsule, and renal sinus soft tissue margin should be evaluated. A positive surgical margin is defined as extension of tumor to the inked surface of the resected specimen. Any benign tissue overlying the tumor, regardless of thickness, renders the margin negative.2,3,4

Total/Radical Nephrectomy: The ureteric, vascular (renal artery and vein), and soft tissue (renal hilar, Gerota’s fascia when appropriate) margins should be evaluated.1 The renal vein margin is more commonly a challenge than the ureter or artery margin, as tumors often extend with finger-like projections into the main renal vein or vena cava. If tumor is present in the vascular lumen but not adherent to, or invading, the wall at the margin by microscopic evaluation, this is considered a negative margin since the tumor may be manipulated backward within the vein before ligation and not transected. Involvement of the Gerota’s fascia/soft tissue margin is very rare in total/radical nephrectomy, except with the highest stage tumors. In this setting, it is usually apparent that the adipose tissue is adherent to the tumor.

References


**H. pTNM Classification**

The TNM staging system of the American Joint Committee on Cancer (AJCC) for renal cell carcinoma is recommended.1

By AJCC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (e.g., when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y”, “r”, and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (i.e., neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (i.e., before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.
Additional Descriptors
For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

Lymphatic and/or Vascular Invasion
By AJCC convention, vessel invasion (lymphatic or venous) does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category. In all other cases, lymphatic and venous invasion by tumor are coded separately.

References

I. Additional Findings in Kidney
It is important to recognize that medical kidney diseases may be present in nonneoplastic renal tissue in nephrectomy and nephroureterectomy specimens. Arterionephrosclerosis (or hypertensive nephropathy) and diabetic nephropathy are seen in approximately 30% and 20% of patients, respectively. Other medical renal diseases that have been identified include thrombotic microangiopathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, amyloidosis, and IgA nephropathy. The findings of greater than 20% global glomerulosclerosis or advanced diffuse diabetic glomerulosclerosis are predictive of significant decline in renal function 6 months after radical nephrectomy.

Evaluation for medical renal disease should be performed in each case; additional special stains, such as PAS and/or Jones methenamine silver stains should be applied if necessary. Consultation with a nephropathologist should be pursued as needed.

However, no studies have specifically measured peritumoral-related changes in the renal cortex. Some tumors have no peritumoral changes (oncocytoma is the best example), whereas some large tumors often have a large zone of peritumoral changes compared with smaller tumors. The pseudocapsule may contain sclerotic glomeruli, tubular atrophy and show fibrointimal thickening of arteries, followed by a zone of several millimeters of acute tubular injury, none of which is representative of the cortex elsewhere. A judgement whether the amount of nonneoplastic renal parenchyma is sufficient for evaluation of medical kidney diseases should be made on a case by case basis. Two studies have used 1 mm to 5 mm as the cut-off for insufficient renal parenchyma. Five millimeters of nonneoplastic renal parenchyma is a reasonable recommendation.

References

